Tandem Diabetes Care (NSDQ:TNDM) said today that its t:slim X2 insulin pump won CE Mark clearance in the European Union.
The San Diego, Calif.-based company plans to start selling the device in international markets in the second half of 2018. Tandem’s latest drug-pump won FDA approval in August last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Tandem wins CE Mark for t:slim X2 insulin pump appeared first on MassDevice.